According to the present invention, as a monomer which is unlikely to be crystallized in a curable composition for manufacturing an optical member and which enables manufacture of a cured product having a high level of moisture-heat resistance, a compound represented by General Formula (A) is provided. ##STR00001## In the formula, Ar.sup.11 and Ar.sup.12 each independently represent an aryl group or a heteroaryl group; X.sup.1, Y.sup.1, X.sup.2, Y.sup.2, Z.sup.1, and Z.sup.2 each independently represent a nitrogen atom or a carbon atom, or the like; Ar.sup.13 and Ar.sup.14 each independently represent an arylene group or a heteroarylene group, where at least one of Ar.sup.13 or Ar.sup.14 is a group other than a phenylene group; R.sup.3 to R.sup.6 each independently represent a substituent, q and r each independently are an integer of 0 to 4, and v and w each independently are an integer of 0 or more; L.sup.1 and L.sup.2 each independently represent a single bond, an oxygen atom, an ester bond, or the like; R.sup.11 and R.sup.12 each independently represent a divalent linking group containing a branched alkylene group; and R.sup.21 and R.sup.22 each independently represent a hydrogen atom or a methyl group.

A phase difference plate includes a phase difference plate P1 and a phase difference plate P2. An in-plane slow axis of the phase difference plate P1 is orthogonal to an in-plane slow axis of the phase difference plate P2. The phase difference plate P2 includes a layer of a liquid crystal material oriented in an in-plane direction. An in-plane retardation ReP2(λ) at a wavelength λ nm of the phase difference plate P2 satisfies the following formulae (e1) and (e2): {Re2(400)−Re2(550)}/{Re2(550)−Re2(700)}<2.90 (e1), and Re2(400)/Re2(700)>1.13 (e2). An in-plane retardation ReP1(λ) of the phase difference plate P1 at a wavelength λ nm and the in-plane retardation ReP2(λ) of the phase difference plate P2 at the wavelength λ nm satisfy the following formulae (e4) and (e5): ReP1(550)>ReP2(550) (e4), and ReP1(400)/ReP1(700)<ReP2(400)/ReP2(700) (e5).

A phase difference plate includes a phase difference plate P1 and a phase difference plate P2. An in-plane slow axis of the phase difference plate P1 is orthogonal to an in-plane slow axis of the phase difference plate P2. The phase difference plate P2 includes a layer of a liquid crystal material oriented in an in-plane direction. An in-plane retardation ReP2(λ) at a wavelength λ nm of the phase difference plate P2 satisfies the following formulae (e1) and (e2): {Re2(400)−Re2(550)}/{Re2(550)−Re2(700)}<2.90 (e1), and Re2(400)/Re2(700)>1.13 (e2). An in-plane retardation ReP1(λ) of the phase difference plate P1 at a wavelength λ nm and the in-plane retardation ReP2(λ) of the phase difference plate P2 at the wavelength λ nm satisfy the following formulae (e4) and (e5): ReP1(550)>ReP2(550) (e4), and ReP1(400)/ReP1(700)<ReP2(400)/ReP2(700) (e5).

A composition for use as a surgical adhesive for the adhesion of a material to a biological tissue, for the adhesion of biological tissues to one another, for the adhesion of a glue or of a substance to the surface of a biological tissue, as a surgical sealant, for blocking or plugging orifices created by a thread suture or staple suture or by a tissue resection, for blocking an orifice, an incision or a tear in a biological tissue, as a hemostatic agent for stopping bleeding, as a dressing on a biological tissue for covering and protecting a wound, for reinforcing a biological tissue, for attaching and stabilizing a biological tissue. The compositions include a polymerizable monomer with a phosphate function or a phosphonate function and a methacrylate function.

A composition for use as a surgical adhesive for the adhesion of a material to a biological tissue, for the adhesion of biological tissues to one another, for the adhesion of a glue or of a substance to the surface of a biological tissue, as a surgical sealant, for blocking or plugging orifices created by a thread suture or staple suture or by a tissue resection, for blocking an orifice, an incision or a tear in a biological tissue, as a hemostatic agent for stopping bleeding, as a dressing on a biological tissue for covering and protecting a wound, for reinforcing a biological tissue, for attaching and stabilizing a biological tissue. The compositions include a polymerizable monomer with a phosphate function or a phosphonate function and a methacrylate function.

A formulation for a photopolymer composite material for a 3D printing system includes an acrylate oligomer, an inorganic hydrate, a reinforcing filler, and an ultraviolet (UV) initiator. In the formulation the acrylate oligomer may be found in the range between about 20.0-60.0 w % of the formulation. The inorganic hydrate may be found in the range between about 20.0-50.0 w % of the formulation. The reinforcing filler may be found in the range between about 5.0-60.0 w % of the formulation, and the UV initiator may be found in the range between about 0.001-0.5 w % of the formulation. A method of generating a formulation of a photopolymer composite material for use in a 3D printing system includes using an acrylate oligomer, an inorganic hydrate, a reinforcing filler, and an ultraviolet (UV) initiator.

A formulation for a photopolymer composite material for a 3D printing system includes an acrylate oligomer, an inorganic hydrate, a reinforcing filler, and an ultraviolet (UV) initiator. In the formulation the acrylate oligomer may be found in the range between about 20.0-60.0 w % of the formulation. The inorganic hydrate may be found in the range between about 20.0-50.0 w % of the formulation. The reinforcing filler may be found in the range between about 5.0-60.0 w % of the formulation, and the UV initiator may be found in the range between about 0.001-0.5 w % of the formulation. A method of generating a formulation of a photopolymer composite material for use in a 3D printing system includes using an acrylate oligomer, an inorganic hydrate, a reinforcing filler, and an ultraviolet (UV) initiator.

A photocurable composition and systems and methods of preparing and curing the photocurable composition are provided. In one example, a photocurable composition includes a photoinitiator mixture, consisting only of a mixture of biocompatible compounds, including one or more of naproxen, caffeine, uracil, quercetin, and cyanocobalamin, and a polymer resin.

A photocurable composition and systems and methods of preparing and curing the photocurable composition are provided. In one example, a photocurable composition includes a photoinitiator mixture, consisting only of a mixture of biocompatible compounds, including one or more of naproxen, caffeine, uracil, quercetin, and cyanocobalamin, and a polymer resin.

A formulation for a photopolymer composite material for a 3D printing system includes an acrylate oligomer, an inorganic hydrate, a reinforcing filler, and an ultraviolet (UV) initiator. In the formulation the acrylate oligomer may be found in the range between about 20.0-60.0 w % of the formulation. The inorganic hydrate may be found in the range between about 20.0-50.0 w % of the formulation. The reinforcing filler may be found in the range between about 5.0-60.0 w % of the formulation, and the UV initiator may be found in the range between about 0.001-0.5 w % of the formulation. A method of generating a formulation of a photopolymer composite material for use in a 3D printing system includes using an acrylate oligomer, an inorganic hydrate, a reinforcing filler, and an ultraviolet (UV) initiator.